Chen-Pin Wang1, Carlos Lorenzo2, Samy L Habib3, Booil Jo4, Sara E Espinoza5. 1. Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio; Geriatrics Research, Education & Clinical Center (GRECC), South Texas Veterans Health Care System. Electronic address: wangc3@uthscsa.edu. 2. Department of Medicine, University of Texas Health Science Center at San Antonio. 3. Geriatrics Research, Education & Clinical Center (GRECC), South Texas Veterans Health Care System; Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio. 4. Department of Psychiatry and Behavioral Sciences, Stanford University. 5. Geriatrics Research, Education & Clinical Center (GRECC), South Texas Veterans Health Care System; Department of Medicine, University of Texas Health Science Center at San Antonio; Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio.
Abstract
AIMS: To identify distinct temporal likelihoods of age-related comorbidity (ARC) diagnoses: cardiovascular diseases (CVD), cancer, depression, dementia, and frailty-related diseases (FRD) in older men with type 2 diabetes (T2D) but ARC naïve initially, and assess the heterogeneous effects of metformin on ARCs and mortality. METHODS: We identified a clinical cohort of male veterans in the United States who were ≥65years old with T2D and free from ARCs during 2002-2003. ARC diagnoses during 2004-2012 were analyzed using latent class modeling adjusted for confounders. RESULTS: The cohort consisted of 41,204 T2D men with age 74.6±5.8years, HbA1c 6.5±0.97%, and 8393 (20.4%) metformin users. Four ARC classes were identified. 'Healthy Class' (53.6%): metformin reduced likelihoods of all ARCs (from 0.14% in dementia to 6.1% in CVD). 'High Cancer Risk Class' (11.6%): metformin reduced likelihoods of CVD (13.3%), cancer (45.5%), depression (5.0%), and FRD (13.7%). 'High CVD Risk Class' (17.4%): metformin reduced likelihoods of CVD (48.6%), cancer (3.2%), depression (2.8%), and FRD (6.3%). 'High Frailty Risk Class' (17.2%): metformin reduced likelihoods of CVD (18.8%), cancer (3.9%), dementia (3.8%), depression (15.6%), and FRD (23.8%). CONCLUSIONS: Metformin slowed ARC development in old men with T2D, and these effects varied by ARC phenotype.
AIMS: To identify distinct temporal likelihoods of age-related comorbidity (ARC) diagnoses: cardiovascular diseases (CVD), cancer, depression, dementia, and frailty-related diseases (FRD) in older men with type 2 diabetes (T2D) but ARC naïve initially, and assess the heterogeneous effects of metformin on ARCs and mortality. METHODS: We identified a clinical cohort of male veterans in the United States who were ≥65years old with T2D and free from ARCs during 2002-2003. ARC diagnoses during 2004-2012 were analyzed using latent class modeling adjusted for confounders. RESULTS: The cohort consisted of 41,204 T2D men with age 74.6±5.8years, HbA1c 6.5±0.97%, and 8393 (20.4%) metformin users. Four ARC classes were identified. 'Healthy Class' (53.6%): metformin reduced likelihoods of all ARCs (from 0.14% in dementia to 6.1% in CVD). 'High Cancer Risk Class' (11.6%): metformin reduced likelihoods of CVD (13.3%), cancer (45.5%), depression (5.0%), and FRD (13.7%). 'High CVD Risk Class' (17.4%): metformin reduced likelihoods of CVD (48.6%), cancer (3.2%), depression (2.8%), and FRD (6.3%). 'High Frailty Risk Class' (17.2%): metformin reduced likelihoods of CVD (18.8%), cancer (3.9%), dementia (3.8%), depression (15.6%), and FRD (23.8%). CONCLUSIONS:Metformin slowed ARC development in old men with T2D, and these effects varied by ARC phenotype.
Authors: Martin Fortin; Gina Bravo; Catherine Hudon; Lise Lapointe; José Almirall; Marie-France Dubois; Alain Vanasse Journal: Qual Life Res Date: 2006-02 Impact factor: 4.147
Authors: Kathleen A Jablonski; Jarred B McAteer; Paul I W de Bakker; Paul W Franks; Toni I Pollin; Robert L Hanson; Richa Saxena; Sarah Fowler; Alan R Shuldiner; William C Knowler; David Altshuler; Jose C Florez Journal: Diabetes Date: 2010-08-03 Impact factor: 9.461
Authors: Jeffrey F Scherrer; Joanne Salas; James S Floyd; Susan A Farr; John E Morley; Sascha Dublin Journal: Mayo Clin Proc Date: 2019-08 Impact factor: 7.616
Authors: Jared M Campbell; Matthew D Stephenson; Barbora de Courten; Ian Chapman; Susan M Bellman; Edoardo Aromataris Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472